Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts.

IF 2.3 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM International Journal of Endocrinology Pub Date : 2023-01-01 DOI:10.1155/2023/9926462
Fengyi Deng, Wenyan Wu, Xingyu Fan, Xing Zhong, Nuojin Wang, Yue Wang, Tianrong Pan, Yijun Du
{"title":"Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts.","authors":"Fengyi Deng,&nbsp;Wenyan Wu,&nbsp;Xingyu Fan,&nbsp;Xing Zhong,&nbsp;Nuojin Wang,&nbsp;Yue Wang,&nbsp;Tianrong Pan,&nbsp;Yijun Du","doi":"10.1155/2023/9926462","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus increases the risk of sarcopenia, which is characterized by decreased muscle mass, strength, and function. However, there are no effective drugs to treat diabetic sarcopenia, and its underlying mechanism remains unknown. Here, we aimed to determine whether the GLP-1 receptor agonist (GLP-1RA) dulaglutide (Dul) affects the progression of diabetic sarcopenia.</p><p><strong>Methods: </strong>db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks. Mouse muscle tissues were then pathologically evaluated and stained with F4/80 or MPO to detect macrophages and neutrophils, respectively. In addition, inflammatory factors and FNDC5 in the muscle tissues were detected using qRT-PCR. Moreover, C2C12 cells were induced to enable their differentiation into skeletal muscle cells, and muscle factor levels were then detected. Furthermore, changes in muscle factor levels were detected at various glucose concentrations (11 mM, 22 mM, and 44 mM).</p><p><strong>Results: </strong>In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1<i>β</i>, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice. In vitro, a C2C12 cell differentiation model was established through the observation of cell morphology and determination of myokine levels. Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited. Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein.</p><p><strong>Conclusions: </strong>Treatment with the GLP-1RA dulaglutide protects db/db mice against skeletal muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. High glucose inhibited the differentiation of C2C12 cells and decreased the mRNA and protein levels of myokines. Dulaglutide could reverse the differentiation state induced in C2C12 cells by high glucose.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425251/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/9926462","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Type 2 diabetes mellitus increases the risk of sarcopenia, which is characterized by decreased muscle mass, strength, and function. However, there are no effective drugs to treat diabetic sarcopenia, and its underlying mechanism remains unknown. Here, we aimed to determine whether the GLP-1 receptor agonist (GLP-1RA) dulaglutide (Dul) affects the progression of diabetic sarcopenia.

Methods: db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks. Mouse muscle tissues were then pathologically evaluated and stained with F4/80 or MPO to detect macrophages and neutrophils, respectively. In addition, inflammatory factors and FNDC5 in the muscle tissues were detected using qRT-PCR. Moreover, C2C12 cells were induced to enable their differentiation into skeletal muscle cells, and muscle factor levels were then detected. Furthermore, changes in muscle factor levels were detected at various glucose concentrations (11 mM, 22 mM, and 44 mM).

Results: In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice. In vitro, a C2C12 cell differentiation model was established through the observation of cell morphology and determination of myokine levels. Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited. Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein.

Conclusions: Treatment with the GLP-1RA dulaglutide protects db/db mice against skeletal muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. High glucose inhibited the differentiation of C2C12 cells and decreased the mRNA and protein levels of myokines. Dulaglutide could reverse the differentiation state induced in C2C12 cells by high glucose.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
杜拉鲁肽通过抑制炎症和调节成肌细胞分化来保护小鼠糖尿病性肌少症介导的肌肉损伤。
背景:2型糖尿病增加了肌肉减少症的风险,其特征是肌肉质量、力量和功能下降。然而,目前还没有有效的药物治疗糖尿病性肌肉减少症,其潜在的机制尚不清楚。在这里,我们的目的是确定GLP-1受体激动剂(GLP-1RA)杜拉鲁肽(Dul)是否影响糖尿病肌肉减少症的进展。方法:给db/db小鼠腹腔注射0.6 mg/kg杜拉鲁肽,持续10周。然后对小鼠肌肉组织进行病理评估,分别用F4/80或MPO染色检测巨噬细胞和中性粒细胞。此外,采用qRT-PCR检测肌肉组织中的炎症因子和FNDC5。并诱导C2C12细胞向骨骼肌细胞分化,检测肌肉因子水平。此外,在不同葡萄糖浓度(11 mM, 22 mM和44 mM)下检测肌肉因子水平的变化。结果:杜拉鲁肽在体内可减轻肌肉组织损伤;炎症因子、IL-1β、IL-6、CCL2和CXCL1水平降低;并逆转了db/db小鼠肌肉组织中FNDC5的水平。在体外,通过观察细胞形态和测定肌因子水平,建立C2C12细胞分化模型。在高糖刺激下,C2C12细胞的分化受到抑制。杜拉鲁肽通过上调FNDC5 mRNA和蛋白水平改善了这种抑制状态。结论:GLP-1RA杜拉鲁肽通过抑制炎症和调节成肌细胞分化对db/db小鼠骨骼肌损伤具有保护作用。高糖抑制C2C12细胞分化,降低肌因子mRNA和蛋白水平。杜拉鲁肽能逆转高糖诱导的C2C12细胞分化状态。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Endocrinology
International Journal of Endocrinology ENDOCRINOLOGY & METABOLISM-
CiteScore
5.20
自引率
0.00%
发文量
147
审稿时长
1 months
期刊介绍: International Journal of Endocrinology is a peer-reviewed, Open Access journal that provides a forum for scientists and clinicians working in basic and translational research. The journal publishes original research articles, review articles, and clinical studies that provide insights into the endocrine system and its associated diseases at a genomic, molecular, biochemical and cellular level.
期刊最新文献
Short-Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic-Psycho Relevance. Relationship between CCL25/CCR9 Levels in Follicular Fluid and High Ovarian Response in Patients with Polycystic Ovary Syndrome. Sex Differences in the Associations among Insulin Resistance Indexes with Metabolic Syndrome: A Large Cross-Sectional Study. Association between Metabolic Syndrome and Musculoskeletal Status: A Cross-Sectional Study of NHANES. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1